Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
February 02 2010 - 8:30AM
PR Newswire (US)
EXTON, Pa., Feb. 2 /PRNewswire-FirstCall/ -- Fibrocell Science,
Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on
the development of regenerative cell therapy for aesthetic, medical
and scientific applications, announced today that David Pernock,
Chairman of the Board of Directors, has been named Chief Executive
Officer (CEO), effective immediately. Pernock most recently served
as Senior Vice President (SVP), Pharmaceuticals, Vaccines
(Biologics), Oncology, Acute Care and HIV at GlaxoSmithKline. He
joined Fibrocell's Board of Directors last September. "I'm pleased
to take on the role of Fibrocell's CEO during this pivotal period
for the company and our lead investigational cell therapy Laviv(TM)
(azficel-T)(1)," said Pernock. "We are excited about the potential
for this therapy as we continue to address the U.S. Food & Drug
Administration's (FDA) requests as outlined in its complete
response letter to our March 2009 biologics license application for
Laviv's use in the treatment of moderate to severe nasolabial fold
wrinkles." Mr. Pernock takes on the role of Fibrocell Science's CEO
with extensive leadership experience in healthcare sales and
commercialization, building business units, partnerships, and
brands at GlaxoSmithKline. During a long career at the
multinational pharmaceutical company that culminated with his role
as SVP, Mr. Pernock was promoted numerous times to levels of
increasing responsibility including Vice President of Marketing,
Pharmaceuticals; Vice President of Sales and Marketing, Oncology;
Vice President of Managed Care; and, Vice President of Sales. Mr.
Pernock holds a B.S. in Business Administration from Arizona State
University. He is a director of Martek Biosciences Corporation and
serves in many philanthropic organizations. "David's proven history
of delivering results across many varied corporate functions makes
him an asset to Fibrocell Science as a CEO," said Declan Daly,
Fibrocell Science, Inc. Chief Operating Officer and Chief Financial
Officer. "He has had a positive impact on the leadership team and
throughout the company as Chairman, and we welcome his broader role
within our organization." About Fibrocell Science, Inc. Fibrocell
Science, Inc. (OTC:FCSC) (BULLETIN BOARD: FCSC) is a biotechnology
company focused on developing regenerative fibroblast cell therapy
for aesthetic, medical and scientific applications. Fibrocell
Science is committed to advancing the scientific, medical and
commercial potential of autologous skin and tissue, as well its
innovative cellular processing technology and manufacturing
excellence. For additional information, please visit
http://www.fibrocellscience.com/. Forward Looking Statements All
statements in this press release that are not based on historical
fact are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 and the provisions
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements in this press release include, without
limitation, the ability of the Company to complete the
histopathology study and provide to the FDA the requested data on a
timely basis. While management has based any forward-looking
statements contained herein on its current expectations, the
information on which such expectations were based may change. These
forward-looking statements rely on a number of assumptions
concerning future events and are subject to a number of risks,
uncertainties, and other factors, many of which are outside of the
Company's control, that could cause actual results to materially
differ from such statements. Such risks, uncertainties, and other
factors include, but are not necessarily limited to, those set
forth under Item 1A "Risk Factors" in the Company's Annual Report
on Form 10-K for the year ended December 31, 2008, as updated in
"Item 1A. Risk Factors" in the Company's Quarterly Reports on Form
10-Q filed since the annual report. The Company operates in a
highly competitive and rapidly changing environment, thus new or
unforeseen risks may arise. Accordingly, investors should not place
any reliance on forward-looking statements as a prediction of
actual results. The Company disclaims any intention to, and
undertakes no obligation to, update or revise any forward-looking
statements. Readers are also urged to carefully review and consider
the other various disclosures in the Company's public filings with
the SEC. (1) The FDA is currently evaluating a proposed brand name,
Laviv(TM). DATASOURCE: Fibrocell Science, Inc. CONTACT: Mike Beyer,
Sam Brown Inc. for Fibrocell Science, Inc., +1-773-463-4211, Web
Site: http://www.fibrocellscience.com/
Copyright